

Page 1 of 5

For personal use only. Not for distribution. For personal use only. Not for distribution.

	ATV	ATV/c	ATV/r	DRV/c	SYM	DRV/r	FPV	IDV	LPV	RTV	SQV	TPV
Antibacterials												
Amikacin	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Amoxicillin	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Ampicillin	🟢	🟢	🟢	🟢	🟡	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Azithromycin	🟠	🟠	🟠	🟢	🟢	🟢	🟢	🟢	🟠	🟢	🔴	🟢
Bedaquiline	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🔴	🟠
Capreomycin	🟢	🟢	🟢	🟢	🟡	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Cefalexin	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Cefazolin	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Cefixime	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Cefotaxime	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Ceftazidime	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Ceftriaxone	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Chloramphenicol	🟡	🟡	🟡	🟡	🟡	🟡	🟡	🟡	🟡	🟡	🟡	🟡
Ciprofloxacin	🟠	🟠	🟠	🟢	🟢	🟢	🟢	🟢	🟠	🟢	🔴	🟢
Clarithromycin	🟠	🟠	🟠	🟠	🟠	🟠	🟢	🟢	🟠	🟠	🔴	🟠
Clavulanic acid	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Clindamycin	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🟠
Clofazimine	🟠	🟠	🟠	🟢	🟢	🟢	🟢	🟢	🟠	🟢	🔴	🟢
Cloxacillin	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Cycloserine	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Dapsone	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🔴	🟢
Delamanid	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🔴	🟠
Doxycycline	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Ertapenem	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Erythromycin	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🔴	🟠
Ethambutol	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Ethionamide	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Flucloxacillin	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Gentamicin	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Imipenem/Cilastatin	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Isoniazid	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Kanamycin	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Levofloxacin	🟠	🟠	🟠	🟢	🟢	🟢	🟢	🟢	🟠	🟢	🔴	🟢
Linezolid	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Meropenem	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Metronidazole	🟢	🟢	🟢	🟢	🟢	🟢	🟠	🟠	🟠	🟠	🟠	🟠
Moxifloxacin	🟠	🟠	🟠	🟢	🟢	🟠	🟠	🟠	🟠	🟠	🔴	🟠
Nitrofurantoin	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Ofloxacin	🟠	🟠	🟠	🟢	🟢	🟢	🟢	🟢	🟠	🟢	🔴	🟢
Para-aminosalicylic acid	🟢	🟢	🟢	🟢	🟡	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Penicillins	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Piperacillin	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Pyrazinamide	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Rifabutin	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🟠
Rifampicin	🔴	🔴	🔴	🔴	🔴	🔴	🔴	🔴	🔴	🔴	🔴	🔴
Rifapentine	🔴	🔴	🔴	🔴	🔴	🔴	🟠	🟠	🟠	🟠	🟠	🟠
Rifaximin	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Spectinomycin	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Streptomycin	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Sulfadiazine	🟢	🟢	🟡	🟢	🟠	🟡	🟡	🟡	🟡	🟡	🟡	🟡
Tazobactam	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Telithromycin	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🔴	🟠
Tetracyclines	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Tinidazole	🟡	🟡	🟡	🟡	🟡	🟡	🟡	🟡	🟠	🟡	🟡	🟡
Trimethoprim/Sulfamethoxazole	🟢	🟢	🟢	🟢	🟡	🟡	🟢	🟢	🟢	🟢	🟢	🟢
Vancomycin	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Anti-coagulant, Anti-platelet and Fibrinolytic												
Acenocoumarol	🟢	🟢	🟢	🟢	🟢	🟠	🟠	🟠	🟠	🟠	🟠	🟠
Apixaban	🔴	🔴	🔴	🔴	🔴	🔴	🔴	🔴	🔴	🔴	🔴	🔴
Argatroban	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Aspirin (anti-platelet)	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Betrixaban	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🔴	🟠
Clopidogrel	🔴	🔴	🔴	🔴	🔴	🔴	🔴	🔴	🔴	🔴	🔴	🔴
Dabigatran	🔴	🔴	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🟠	🟠
Dalteparin	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Dipyridamole	🟠	🟠	🟠	🟢	🟢	🟠	🟠	🟠	🟠	🟠	🟠	🟠
Edoxaban	🟠	🟠	🟠	🟢	🟢	🟢	🟢	🟢	🟠	🟢	🟢	🟢
Enoxaparin	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Fondaparinux	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Heparin	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Phenprocoumon	🟠	🟠	🟠	🟢	🟠	🟢	🟠	🟠	🟠	🟠	🟠	🟠
Prasugrel	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢
Rivaroxaban	🔴	🔴	🔴	🔴	🔴	🔴	🔴	🔴	🔴	🔴	🔴	🔴
Streptokinase	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟠
Ticagrelor	🔴	🔴	🔴	🔴	🔴	🔴	🔴	🔴	🔴	🔴	🔴	🔴
Warfarin	🟠	🟠	🟠	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢	🟢

●	These drugs should not be coadministered
■	Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

© Liverpool Drug Interaction Group, University of Liverpool, Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Charts revised February 2021. Full information available at www.hiv-druginteractions.org

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

	ATV	ATV/c	ATV/r	DRV/c	SYM	DRV/r	FPV	IDV	LPV	RTV	SQV	TPV
Antifungals												
Amphotericin B	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Anidulafungin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Caspofungin	▲	▲	▲	◆	◆	◆	◆	◆	◆	◆	◆	◆
Fluconazole	◆	▲	◆	▲	▲	◆	◆	◆	◆	◆	◆	▲
Flucytosine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Griseofulvin	■	■	■	■	■	■	■	■	■	■	■	■
Itraconazole	◆	◆	◆	◆	◆	◆	■	■	■	■	■	■
Ketoconazole	■	■	■	■	■	■	■	■	■	■	■	■
Miconazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nystatin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Posaconazole	■	■	■	■	■	■	■	■	■	■	■	■
Terbinafine	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲
Voriconazole	■	■	■	■	■	■	■	■	■	●	■	■
Antihistamines												
Astemizole	●	●	●	●	●	●	●	●	●	●	●	●
Cetirizine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Chlorphenamine	◆	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲	■
Diphenhydramine	◆	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲	■
Fexofenadine	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲	■
Levocetirizine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Loratadine	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲	■
Promethazine	◆	▲	▲	▲	▲	▲	▲	▲	▲	▲	▲	■
Terfenadine	●	●	●	●	●	●	●	●	●	●	●	●
Antimigraine Agents												
Almotriptan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Dihydroergotamine	●	●	●	●	●	●	●	●	●	●	●	●
Eletriptan	●	●	●	●	●	●	●	●	●	●	●	●
Ergotamine	●	●	●	●	●	●	●	●	●	●	●	●
Rizatriptan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Sumatriptan	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Zolmitriptan	■	■	■	■	■	■	■	■	■	■	■	■
Antiprotozoals												
Amodiaquine	▲	▲	▲	◆	◆	▲	▲	▲	▲	▲	▲	■
Artemisinin	■	■	■	■	■	■	■	■	■	■	■	■
Atovaquone	◆	◆	■	◆	◆	■	■	■	■	■	■	■
Benznidazole	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Chloroquine	■	■	■	▲	▲	▲	◆	◆	■	◆	●	◆
Diloxanide	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Eflornithine	◆	◆	◆	◆	▲	◆	◆	◆	◆	◆	◆	◆
Halofantrine	●	●	●	●	●	●	●	●	●	●	●	●
Hydroxychloroquine	■	■	■	▲	▲	▲	▲	▲	■	▲	●	▲
Lumefantrine	■	■	■	■	■	■	■	■	■	■	■	■
Mefloquine	■	■	■	■	■	■	■	■	■	■	●	■
Meglumine antimoniate	■	■	■	◆	◆	◆	■	■	■	◆	●	◆
Melarsoprol	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Miltefosine	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Nifurtimox	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Paromomycin	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Pentamidine	■	■	■	◆	◆	◆	■	■	■	◆	●	◆
Piperazine	■	■	■	■	■	■	■	■	■	■	■	■
Primaquine	■	■	■	◆	◆	◆	■	■	■	◆	●	◆
Proguanil	◆	◆	◆	◆	◆	◆	■	■	■	■	■	■
Pyrimethamine	◆	◆	◆	◆	▲	◆	◆	◆	◆	◆	◆	◆
Quinine	■	■	■	■	■	■	■	■	■	■	●	■
Sodium stibogluconate	■	■	■	◆	◆	◆	◆	◆	■	◆	◆	◆
Sulfadoxine	◆	◆	◆	◆	▲	◆	◆	◆	◆	◆	◆	◆
Antipsychotics/Neuroleptics												
Amisulpride	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
Aripiprazole	■	■	■	■	■	■	■	■	■	■	●	■
Asenapine	■	■	■	▲	▲	▲	■	■	■	■	●	■
Chlorpromazine	■	■	■	▲	▲	▲	▲	▲	■	▲	●	▲
Clozapine	■	■	■	■	■	■	■	●	■	■	●	■
Fluphenazine	■	■	■	▲	▲	▲	▲	▲	■	■	●	■
Haloperidol	■	■	■	▲	▲	▲	▲	▲	■	▲	●	▲
Iloperidone	■	■	■	■	■	■	■	■	■	■	●	■
Levomepromazine	■	■	■	▲	▲	▲	▲	▲	■	▲	●	▲
Olanzapine	◆	◆	◆	◆	◆	■	■	■	■	■	■	■
Paliperidone	■	■	■	■	■	■	▲	▲	■	▲	▲	●
Perazine	■	■	■	■	■	■	■	■	■	■	■	■
Periciazine	■	■	■	▲	▲	▲	▲	▲	■	▲	●	■
Perphenazine	■	■	■	▲	▲	▲	▲	▲	■	▲	●	■
Pimozide	●	●	●	■	■	●	■	■	●	■	●	■
Pipotiazine	■	■	■	▲	▲	▲	▲	▲	■	▲	●	■
Quetiapine	●	●	●	●	●	●	●	●	●	●	●	●
Risperidone	■	■	■	■	■	■	■	■	■	■	■	■
Sulpiride	■	■	■	◆	◆	◆	◆	◆	◆	◆	●	◆
Thioridazine	■	■	■	▲	▲	▲	▲	▲	■	▲	●	■
Tiapride	■	■	■	◆	◆	◆	◆	◆	◆	◆	◆	◆
Ziprasidone	●	●	●	■	■	■	■	■	●	■	●	■
Zotepine	■	■	■	■	■	■	■	■	■	■	■	■
Zuclophenixol	■	■	■	■	■	■	■	■	■	■	●	■

ATV	Atazanavir alone (Reyataz [®])	FPV	Fosamprenavir (Telzir [®] , Lexiva [®])
ATV/c	Atazanavir/cobicistat (Evotaz [®])	LPV	Lopinavir (Kaletra [®])
ATV/r	Atazanavir + Ritonavir (Reyataz [®] +Norvir [®])	RTV	Ritonavir (Norvir [®])
DRV/c	Darunavir/cobicistat (Rezolista [®] , Prezcoibix [®])	SQV	Saquinavir (Invirase [®])
SYM	Darunavir/cobicistat/FTC/TAF (Symtuza [®])	TPV	Tipranavir (Aptivus [®])
DRV/r	Darunavir + Ritonavir (Prezista [®] +Norvir [®])		

●	These drugs should not be coadministered
■	Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Where advice differs between countries, and/or between boosted and unboosted regimens, the charts reflect the more cautious option.

© Liverpool Drug Interaction Group, University of Liverpool, Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GE

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Page 3 of 5

For personal use only. Not for distribution. For personal use only. Not for distribution.

[illegible]

●	These drugs should not be coadministered
■	Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Page 4 of 5

For personal use only. Not for distribution. For personal use only. Not for distribution.

Key to abbreviations			
ATV	Atazanavir alone (Reyataz [®])	FPV	Fosamprenavir (Telzir [®] , Lexiva [®])
ATV/c	Atazanavir/cobicistat (Evotaz [®])	LPV	Lopinavir (Kaletra [®])
ATV/r	Atazanavir + Ritonavir (Reyataz [®] +Norvir [®])	RTV	Ritonavir (Norvir [®])
DRV/c	Darunavir/cobicistat (Rezolsta [®] , Prezcoibix [®])	SQV	Saquinavir (Invirase [®])
SYM	Darunavir/cobicistat/FTC/TAF (Symtuza [®])	TPV	Tipranavir (Aptivus [®])
DRV/r	Darunavir + Ritonavir (Prezista [®] +Norvir [®])		

Key to symbols	
●	These drugs should not be coadministered
■	Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Where advice differs between countries, and/or between boosted and unboosted regimens, the charts reflect the more cautious option

© Liverpool Drug Interaction Group, University of Liverpool, Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GE

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Page 5 of 5

For personal use only. Not for distribution. For personal use only. Not for distribution.

Key to abbreviations			
ATV	Atazanavir alone (Reyataz [®])	FPV	Fosamprenavir (Telzir [®] , Lexiva [®])
ATV/c	Atazanavir/cobicistat (Evotaz [®])	LPV	Lopinavir (Kaletra [®])
ATV/r	Atazanavir + Ritonavir (Reyataz [®] +Norvir [®])	RTV	Ritonavir (Norvir [®])
DRV/c	Darunavir/cobicistat (Rezolsta [®] , Prezcoibix [®])	SQV	Saquinavir (Invirase [®])
SYM	Darunavir/cobicistat/FTC/TAF (Symtuza [®])	TPV	Tipranavir (Aptivus [®])
DRV/r	Darunavir + Ritonavir (Prezista [®] +Norvir [®])		

© Liverpool Drug Interaction Group, University of Liverpool, Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GE

© Liverpool Drug Interaction Group, University of Liverpool, Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF

Key to symbols	
●	These drugs should not be coadministered
■	Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected